[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503336":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":29,"studyPopulation":30,"armGroups":25,"interventions":31,"overallOfficials":25,"centralContacts":25,"locations":36,"responsibleParty":65,"collaborators":25,"id":69,"slug":25,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":70,"sex":76,"minAge":77,"maxAge":25,"enrollmentInfo":78,"targetDuration":81,"studyType":82,"phases":25,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Dongzhimen Hospital, Beijing","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"Proportion of patients independent","Proportion of patients independent is defined as the modified Rankin Scale score of 0, 1, or 2.","90 days",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"National Institute of Health Stroke Scale","The National Institute of Health Stroke Scale (NIHSS) ranges from 0 to 42, with higher scores indicating more severe neurological deficits.","The change from baseline to day 10 or discharge.",{"measure":19,"description":20,"timeFrame":17},"Glasgow Coma Scale","The Glasgow Coma Scale (GCS) is used to describe the extent of impaired consciousness in all types of acute medical and trauma patients, ranging from 0 to 15, with lower scores indicating more severe impaired consciousness.",{"measure":22,"description":23,"timeFrame":24},"Patient reported outcome","The patient reported outcome (PRO) scale of stroke consists of four dimensions including the influence on physical, emotional, and social functioning, as well as the overall satisfaction with treatment.","At day 10 or discharge.",null,{"allocation":25,"interventionModel":25,"interventionModelDescription":25,"primaryPurpose":25,"observationalModel":27,"timePerspective":28,"maskingInfo":25},"COHORT","PROSPECTIVE","Suhexiang Pill, a traditional Chinese patent medicine, is widely used in China for acute stroke. However, there is a lack of evidence of its efficacy and safety for acute ischemic stroke in real-world setting. This registry study will recruit 1000 patients who receive Suhexiang Pill treatment after acute ischemic stroke.","Patients diagnosed with Acute ischemic stroke.",[32],{"type":33,"name":34,"description":35,"armGroupLabels":25,"otherNames":25},"DRUG","Suhexiang Pill","Suhexiang Pill is an approved traditional Chinese patent medicine.",[37,57],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Dongzhimen Hospital","NOT_YET_RECRUITING","Beijing","Beijing Municipality","100700","China","CN",{"type":46,"coordinates":47},"Point",[48,49],116.39723,39.9075,{"lat":49,"lon":48},[52],{"name":53,"role":54,"phone":55,"phoneExt":25,"email":56},"Xinxing Lai, M.D.","CONTACT","15901111280","new-star@163.com",{"facility":38,"status":58,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":59,"geoPoint":61,"contacts":62},"RECRUITING",{"type":46,"coordinates":60},[48,49],{"lat":49,"lon":48},[63],{"name":53,"role":54,"phone":64,"phoneExt":25,"email":56},"08615901111280",{"type":66,"investigatorFullName":67,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Ying Gao","Professor","100503336",false,"NCT05833932","Suhexiang Pill for Acute Ischemic Stroke: A Registry Study","Suhexiang Pill for Acute Ischemic Stroke: A Prospective Registry Study of Real-world Data","SUNRISE","Inclusion Criteria:\n\n* Acute ischemic stroke within 7 days of symptom onset.\n* Age ≥ 18\n* Patient who has received Suhexiang Pill treatment\n* Patient or legally authorized representative has signed informed consent.\n\nExclusion Criteria:\n\n* Be allergic to Suhexiang Pill\n* Known to be pregnant or breastfeeding.\n* With conditions that render outcomes or follow-up unlikely to be assessed.","ALL","18 Years",{"count":79,"type":80},1000,"ESTIMATED","1 Year","OBSERVATIONAL","The primary purpose of this study is to investigate the effectiveness and safety of the Suhexiang Pill for patients with acute ischemic stroke in real-world settings.",[85],"Ischemic Stroke",[87,88,89],"acute ischemic stroke","traditional Chinese medicine","registry study","2024-06-10",{"date":92,"type":93},"2024-06-11","ACTUAL",{"date":95,"type":93},"2023-06-01",{"date":97,"type":80},"2024-12-31",{"name":5,"class":6},2]